{'fraction_non_alphanumeric': 0.019849418206707735, 'fraction_numerical': 0.012320328542094456, 'mean_word_length': 5.928909952606635, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Evaluation of peripheral blood lymphocyte subpopulations in stage D prostatic cancer patients].

EVALUATION OF PERIPHERAL BLOOD LYMPHOCYTE SUBPOPULATIONS IN STAGE D PROSTATIC CANCER PATIENTS Tatsuo Morita, Shuji Ohba, Akihiko Tokue and Yasuyuki Yonese From the Department of Urology, Jichi Medical School, Tochigi, Japan Peripheral blood lymphocyte subpopulations both in 38 stage D prostatic cancer patients and in 20 age-matched healthy volunteers were analysed using monoclonal antibodies including OKT3, OKT4, OKT8, OKMl, Leu7 and Leulla. In untreated stage D prostatic cancer patients, the proportion of OKT3+ cells and OKT4+ cells decreased, while the proportion of OKT8+ cells and Leu7+ cells increased significantly resulting in declined OKT4/OKT8 ratio. To determine whether hormone therapy including castration and administration of Estramustine phosphate (EMP) can alter peripheral blood lymphocyte subpopulations, we analysed them before and 3 to 4weeks after hormone therapy. Although the serum level of prostatic acid phosphatase was significantly reduced 3 to 4weeks after hormone therapy, there was no significant alteration in peripheral blood lymphocyte subpopulations either after castration or after a period of EMP administration. These results suggest that quntitative changes in peripheral blood lymphocyte subpopulations may be one of the factors responsible for the immunosuppression in patients with stage D prostatic cancer patients.